comparemela.com

Page 3 - Laura Gault News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sage Therapeutics trims staff by 40% following depression drug setback

The cuts, including several C-suite exits, come in the wake of the FDA’s decision not to approve Sage and partner Biogen’s drug for major depression.

Marc goodmanLaura gaultAl robichaudJim dohertyBarry greeneChris benecchiDrug administrationSage therapeuticsMike quirk

FDA Approves New Pill for Postpartum Depression

The FDA just approved zuranolone, a new medication to treat postpartum depression. The drug is in pill form and meant to be taken once a day for 14 days for fast-acting treatment.

United statesLaura gaultChristopher zahnElizabethm fitelsonHealth equityColumbia university department of psychiatrySage therapeutics incBiogen incDrug administrationWomen programAmerican college of obstetricsSage therapeuticsClinical practiceAmerican collegeNovel approachDepression treatment

EMA grants ODD to Sage Therapeutics SAGE-718 to treat Huntington s disease

EMA has granted Orphan Drug Designation to biopharmaceutical company Sage Therapeutics’ SAGE-718 for the treatment of Huntington’s disease (HD).

Laura gaultOrphan drug designation

Sage Therapeutics, Inc : Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington s Disease

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug

Dennis riedlHelen rubinsteinMatthew hensonLaura gaultExchange commissionSage therapeutics incEuropean medicines agencySage therapeuticsOrphan drug designationChief medical officerProtocol assistanceFast track designationPrivate securities litigation reform act

Sage Therapeutics, Inc (NASDAQ:SAGE) Q4 2022 Earnings Call Transcript

Operator: Good morning. Welcome to the Sage Therapeutics Fourth Quarter and Full-Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

United statesChris benecchiKimi iguchiBarry greeneHelen rubinsteinJim dohertyTazeen ahmadLaura gaultSage therapeutics incHealth photoBrain healthSage therapeuticsCall transcript februarySage therapeutic fourth quarterResults conferenceInvestor relations

vimarsana © 2020. All Rights Reserved.